

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 November 2021 (25.11.2021)



(10) International Publication Number
WO 2021/236876 A3

(51) International Patent Classification:

C07B 59/00 (2006.01) C07D 498/04 (2006.01)
A61K 31/424 (2006.01) A61K 31/4353 (2006.01)

(21) International Application Number:

PCT/US2021/033315

(22) International Filing Date:

20 May 2021 (20.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/027,923	20 May 2020 (20.05.2020)	US
63/027,953	20 May 2020 (20.05.2020)	US
63/028,457	21 May 2020 (21.05.2020)	US
63/028,472	21 May 2020 (21.05.2020)	US

(71) Applicant: **CERTEGO THERAPEUTICS INC.**
[US/US]; 3 Bioscience Park Dr., Farmingdale, NY 11735 (US).

(72) Inventors; and

(71) Applicants: **OSTEN, Pavel** [US/US]; 30 West 13th Street, Apt 6A, New York City, NY 10011 (US). **BALDWIN, Kristin** [US/US]; 30 West 13th Street, Apt 6A, New York City, NY 10011 (US). **DEVITA, Robert** [US/US]; 332 W. Dudley Avenue, Westfield, NJ 07090 (US). **DES-JARDINS, Sam** [CA/CA]; 184 Rue Chauvin, Boisbriand, QC J7G 2N5 (CA). **ALBERT, Jeffrey** [CA/CA]; 413-4041 des Sources, Boulevard Montreal, QC H9B 2A4 (CA).

(74) Agent: **POSTOLSKI, David**; Gearhart Law LLC, 41 River Road, Innovation Plaza, Suite 1A, Summit, NJ 07901 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

06 January 2022 (06.01.2022)

(54) Title: RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS




FIG.1A

(57) Abstract: Ring deuterated gaboxadol is provided. The ring deuterated gaboxadol is useful in the treatment of psychiatric disorders and is more effective than non-deuterated gaboxadol in such treatments. Deuterated gaboxadol is useful in combinations with other compounds to provide additive and synergistic effects for patient therapies. In a specific embodiment, the deuterated gaboxadol is d6-gaboxadol.



WO 2021/236876 A3